dc.contributor.author | Fountzilas, George | en |
dc.contributor.author | Nikolaides, C. | en |
dc.contributor.author | Bafaloukos, Dimitrios | en |
dc.contributor.author | Kalogera-Fountzila, Anna | en |
dc.contributor.author | Kalofonos, H. P. | en |
dc.contributor.author | Samelis, G. | en |
dc.contributor.author | Aravantinos, Gerasimos | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Fountzilas, George | en |
dc.creator | Nikolaides, C. | en |
dc.creator | Bafaloukos, Dimitrios | en |
dc.creator | Kalogera-Fountzila, Anna | en |
dc.creator | Kalofonos, H. P. | en |
dc.creator | Samelis, G. | en |
dc.creator | Aravantinos, Gerasimos | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:53:05Z | |
dc.date.available | 2018-06-22T09:53:05Z | |
dc.date.issued | 2000 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41654 | |
dc.description.abstract | A phase II study was conducted to evaluate the activity and toxicity profile of the combination of docetaxel and gemcitabine in anthracycline- resistant advanced breast cancer (ABC). Thirty-nine eligible patients with a median performance status of 1 (range, 0-2) were enrolled in the study. Treatment consisted of docetaxel 75 mg/m2 in a 1-hr infusion on day 1 preceded by gemcitabine 1000 mg/m2 over 30 min on days 1 and 8. One hundred eighty-one treatment cycles were administered, 113 (62.4%) of them at full dose. Relative dose intensity of gemcitabine and of docetaxel was O.73 and 0.85, respectively. More common grade 3-4 toxicities included neutropenia (49%), anemia (10%), fatigue (10%), nausea/vomiting (8%), and alopecia (77%). Seven patients were hospitalized for febrile neutropenia. Granulocyte colony- stimulating factor (G-CSF) administration was required in 90% of patients. Overall, 14 patients (36%) responded, 3 (7.5%) of them completely. Median duration of response was 10.3 months (range, 4.6-17.5+). Median time to progression was 7 months (range, 0.2-17.5+) and median survival 12.7 months (range, 2-20.5+). In conclusion, the combination of docetaxel and gemcitabine, as used in the present study, has moderate activity in anthracycline-resistant ABC. Future studies should incorporate prophylactic administration of G-CSF to reduce the incidence of febrile neutropenia and maintain dose intensity. | en |
dc.language.iso | eng | en |
dc.source | Cancer investigation | en |
dc.subject | Article | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Breast cancer | en |
dc.subject | Breast neoplasms | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Cancer growth | en |
dc.subject | Cancer survival | en |
dc.subject | Neoplasm | en |
dc.subject | Priority journal | en |
dc.subject | Alopecia | en |
dc.subject | Anemia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Drug resistance | en |
dc.subject | Drug resistance | en |
dc.subject | Fatigue | en |
dc.subject | Febrile neutropenia | en |
dc.subject | Gemcitabine | en |
dc.subject | Neutropenia | en |
dc.subject | Ondansetron | en |
dc.subject | Phase 2 clinical trial | en |
dc.subject | Taxoids | en |
dc.subject | Granulocyte colony stimulating factor | en |
dc.subject | Docetaxel | en |
dc.subject | Survival rate | en |
dc.subject | Gastrointestinal symptom | en |
dc.subject | Antineoplastic | en |
dc.subject | Deoxycytidine | en |
dc.subject | Paclitaxel | en |
dc.subject | Antibiotics | en |
dc.subject | Anthracycline | en |
dc.subject | Patient compliance | en |
dc.title | Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: A hellenic cooperative oncology group phase II study | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 18 | |
dc.description.issue | 6 | |
dc.description.startingpage | 503 | |
dc.description.endingpage | 509 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Aravantinos, Gerasimos [0000-0002-2106-1713] | |
dc.contributor.orcid | Kalogera-Fountzila, Anna [0000-0002-6801-3129] | |
dc.contributor.orcid | Kalofonos, H. P. [0000-0002-3286-778X] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-2106-1713|0000-0002-6801-3129 | |
dc.gnosis.orcid | 0000-0002-3286-778X | |